

From: Sweeney, Colleen
Sent: Friday, April 01, 2016 4:05 PM
To: Margaretten, Nadine (nadine_margaretten@merck.com)
Subject: RE: STN 125592/0 Information Request

Dear Dr. Margaretten:

We have the following requests for additional information regarding your BLA:

1. Please provide Standard Operating Procedures (SOPs) for all of the release tests described in Sections 3.2.S.4.2 and 3.2.P.5.2 - Analytical Procedures.
2. The Clinical Study Report (CSR) provided for clinical study P001 (Section 5.3.5.1) lists the clinical supplies dispensed to subjects as manufacturing lot numbers; (b) (4) . The placebo lots are indicated as (b) (4) (pages 4 and 5 of 637). Please indicate the section of Module 3 that contains the product information regarding the above listed drug product and placebo batches used in study P001.
3. Section 3.2.R (Regional Information) contains drug substance batch records written in Danish. Please provide executed batch records for the commercial scale drug substance batches in English.
4. Please provide the Microsoft Word version of the proposed labeling text in Section 1.14.1.3 as stated in your cover letter for this submission.

Please submit the above information as an amendment to STN 125592/0.

5. Please be aware that the Proper Name for your product is, "House Dust Mite (*Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*) Allergen Extract."

Thank you.

Colleen Sweeney R.N., M.S.
Captain, USPHS
Division of Vaccines & Related Product Applications
Office of Vaccines Research & Review
Center for Biologics Evaluation & Research
US Food & Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993-0002.
Tel: +1 301 796 2640
E-Fax: +1 301 402 0004; Fax: +1 301 827 3075
E. Mail: colleen.sweeney@fda.hhs.gov

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED
AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED

FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.